Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
APOL1 variants change C-terminal conformational dynamics and binding to SNARE protein VAMP8
Sethu M. Madhavan, John F. O’Toole, Martha Konieczkowski, Laura Barisoni, David B. Thomas, Santhi Ganesan, Leslie A. Bruggeman, Matthias Buck, John R. Sedor
Sethu M. Madhavan, John F. O’Toole, Martha Konieczkowski, Laura Barisoni, David B. Thomas, Santhi Ganesan, Leslie A. Bruggeman, Matthias Buck, John R. Sedor
View: Text | PDF
Research Article Nephrology

APOL1 variants change C-terminal conformational dynamics and binding to SNARE protein VAMP8

  • Text
  • PDF
Abstract

APOL1 variants in African populations mediate resistance to trypanosomal infection but increase risk for kidney diseases through unknown mechanisms. APOL1 is expressed in glomerular podocytes and does not vary with underlying kidney disease diagnoses or APOL1 genotypes, suggesting that the kidney disease–associated variants dysregulate its function rather than its localization or abundance. Structural homology searches identified vesicle-associated membrane protein 8 (VAMP8) as an APOL1 protein interactor. VAMP8 colocalizes with APOL1 in the podocyte, and the APOL1:VAMP8 interaction was confirmed biochemically and with surface plasmon resonance. APOL1 variants attenuate this interaction. Computational modeling of APOL1’s 3-dimensional structure, followed by molecular dynamics simulations, revealed increased motion of the C-terminal domain of reference APOL1 compared with either variant, suggesting that the variants stabilize a closed or autoinhibited state that diminishes protein interactions with VAMP8. Changes in ellipticity with increasing urea concentrations, as assessed by circular dichroism spectroscopy, showed higher conformational stability of the C-terminal helix of the variants compared with the reference protein. These results suggest that reference APOL1 interacts with VAMP8-coated vesicles, a process attenuated by variant-induced reduction in local dynamics of the C-terminal. Disordered vesicular trafficking in the podocyte may cause injury and progressive chronic kidney diseases in susceptible African Americans subjects.

Authors

Sethu M. Madhavan, John F. O’Toole, Martha Konieczkowski, Laura Barisoni, David B. Thomas, Santhi Ganesan, Leslie A. Bruggeman, Matthias Buck, John R. Sedor

×

Figure 3

Apolipoprotein L1 interacts with vesicle-associated membrane protein 8 and colocalizes in vitro and in podocytes of human kidney.

Options: View larger image (or click on image) Download as PowerPoint
Apolipoprotein L1 interacts with vesicle-associated membrane protein 8 a...
(A) Representative Western blot of immunopreciptates and whole cell lysates from 293T cells transfected with myc-FLAG–tagged vesicle-associated membrane protein 8 (VAMP8) and carboxy terminal GFP-tagged apolipoprotein L1 (APOL1) plasmids as shown. Full-length GFP-tagged APOL1-G0, but not APOL1 lacking the trypanosomal serum resistance–associated (SRA) protein–interacting domain (aa 339–398), coimmunoprecipitated with myc-FLAG–tagged VAMP8 using an anti-Myc antibody. Rabbit IgG was used for control immunoprecipitation experiments (n = 3). (B) Transiently expressed GFP-tagged APOL1-G0 (green) and myc-FLAG–tagged VAMP8 (red) colocalize in a vesicular pattern in HeLa cells (scale bars: 10 μm). (C) Endogenous APOL1 (red) and VAMP8 (green) colocalize in podocytes of normal human kidney (scale bars: 50 μm). (D) APOL1 (red) in basolateral domains of proximal tubules does not colocalize with VAMP8 (green), which is present in an apical distribution (scale bars: 50 μm). (E) Localization of VAMP8 (green) within glomerular podocytes was confirmed by costaining with glomerular epithelial protein 1 (GLEPP1) (red), a podocyte marker, in normal human kidney (scale bars: 50 μm). VAMP8 staining was also detectable in other glomerular cell types. In all images, nuclei were stained with TOTO-3 iodide (scale bars: 2 μm [inset]).

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts